GlassScriptPhysician profile
Dean Hugh Stephens
NPI 1134256381
$11,809.54
in general payments reported to CMS, 2019-2025
34 companies · $2,212 in 2025
The $2,212 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,011 · 2020: $993 · 2021: $688 · 2022: $2,142 · 2023: $1,794 · 2024: $1,969 · 2025: $2,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,903 · Education: $72.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,903.26 |
| Education | $72.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,790.78 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $1,538.98 | 2019-2025 | Enbrel, Tavneos, Otezla |
| E.R. Squibb & Sons, L.L.C. | $1,135.33 | 2019-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $1,096.68 | 2019-2025 | |
| Abbvie INC. | $1,087.61 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Astrazeneca Pharmaceuticals LP | $694.60 | 2022-2025 | Saphnelo, Evusheld |
| Ucb, INC. | $622.54 | 2019-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $574.23 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $530.13 | 2019-2025 | Actemra |
| Lilly USA, LLC | $455.63 | 2019-2025 | Taltz, Zepbound |
| Celgene Corporation | $429.07 | 2019 | |
| Mallinckrodt Hospital Products INC. | $368.11 | 2023-2025 | Acthar |
| Glaxosmithkline, LLC. | $304.57 | 2020-2025 | Benlysta |
| Pfizer INC. | $135.66 | 2019-2025 | |
| Genzyme Corporation | $111.81 | 2020-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $110.09 | 2024-2025 | Octagam Immune Globulin (Human), Panzyga |
| Radius Health, INC. | $103.26 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.32 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $87.13 | 2022-2025 | Lupkynis |
| Depuy Synthes Sales INC. | $79.89 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $77.23 | 2025 | Purified Cortrophin Gel |
| Grifols USA, LLC | $60.27 | 2023 | Xembify |
| Tersera Therapeutics LLC | $54.19 | 2025 | Quzyttir |
| Alexion Pharmaceuticals, INC. | $52.62 | 2022-2024 | Strensiq |
| Zyla Life Sciences, INC. | $40.24 | 2019 | |
| Fresenius Kabi USA, LLC | $35.11 | 2023-2025 | Tyenne, Idacio |
| Hospira, INC. | $26.79 | 2022 | |
| Sobi, INC | $19.28 | 2025 | |
| Hikma Pharmaceuticals USA | $15.98 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.49 | 2023 | Truxima |
| Medexus Pharma, INC. | $15.13 | 2019 | |
| Merck Sharp & Dohme LLC | $13.37 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.23 | 2020 | |
| Ferring Pharmaceuticals INC. | $13.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.